The grant, stated plainly. On January 18, 2022, PharmaMar was issued US11224663B2, "Antibody drug conjugates." The CPC tags pair the conjugation series — A61K 47/6803/6849/6855 — with distinctive payload-chemistry claims (the C07D 309 pyran series), reflecting a payload class that differs from the common camptothecin and auristatin families.
Why an event-driven desk notes payload choice: in a crowded ADC field, differentiation often comes from the payload — its potency, its mechanism, and its therapeutic window. A conjugate built on a distinct payload class is making a specific bet that its mechanism will carve out space the dominant payloads cannot. That bet is what clinical readouts test.
The disciplined read: a conjugate grant with novel payload chemistry is an exclusivity claim on a specific construction, not a clinical result. The business stakes ride on whether the payload's differentiated mechanism translates into a better window in patients — answered by data, not the patent.
What the grant does not say: nothing about efficacy, safety, or approval, and nothing about how the payload compares head-to-head with established classes. Those are separate facts in separate records.
The takeaway: when scanning ADC programs, read the payload-chemistry claims to understand each program's differentiation bet. PharmaMar's January 2022 conjugate grant is a dated example of a distinct-payload approach in a crowded class.